ETONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Eton Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$49.22−1.09 (-2.17%)
Close on Oct 19, 2026
- Market cap
- $1.61B
- P/E (TTM)
- 126.2
- Dividend yield
- –
Eton Pharmaceuticals, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License [Member] | $0 | $0 | $3.29M | $3.29M | $3.79M | $3.79M | $500.00K | $500.00K | $0 | $5.50M | $5.50M | $10.50M | 0.0% | -100.0% |
| Product Sales and Royalties [Member] | – | $86.93M | $76.66M | $67.03M | $54.40M | $44.54M | $38.51M | $34.18M | $31.38M | $28.80M | $26.14M | $22.33M | – | – |
By region
From the segment and revenue-disaggregation notes of Eton Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.